StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 14:49:01 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Viatris Inc (VTRS) 4200 contracts of July 15 puts trade http://www.streetinsider.com/Options/Viatris+Inc+%28VTRS%29+4200+contracts+of+July+15+puts+trade/26557149.html <p>Viatris Inc (NASDAQ: VTRS) 30-day option implied volatility is at 31; compared to its 52-week range of 26 to 79 with a focus on 4200 contracts of July 15 puts.</p> http://www.streetinsider.com/Options/Viatris+Inc+%28VTRS%29+4200+contracts+of+July+15+puts+trade/26557149.html Wed, 27 May 2026 14:49:01 -0400 VTRS Viatris (VTRS) PT Raised to $22 at Barclays http://www.streetinsider.com/Analyst+PT+Change/Viatris++%28VTRS%29+PT+Raised+to+%2422+at+Barclays/26516114.html Barclays analyst Glen Santangelo raised the price target on Viatris (NASDAQ: VTRS) to $22.00 (from $17.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Viatris++%28VTRS%29+PT+Raised+to+%2422+at+Barclays/26516114.html Tue, 19 May 2026 03:58:55 -0400 VTRS FDA accepts Viatris drug application for fast-acting meloxicam pain treatment http://www.streetinsider.com/Corporate+News/FDA+accepts+Viatris+drug+application+for+fast-acting+meloxicam+pain+treatment/26510552.html <p>The U.S. Food and Drug Administration has accepted Viatris Inc.'s (NASDAQ: VTRS) new drug application for MR-107A-02, a fast-acting meloxicam formulation intended to treat moderate-to-severe acute pain. The FDA assigned a PDUFA goal date of December 27, 2026.</p><p>The application is supported by data from two Phase 3 clinical trials that evaluated the drug following herniorrhaphy and bunionectomy surgeries. Both randomized, double-blind studies compared the investigational drug against placebo and included tramadol as an active control to validate the pain models.</p><p>In the herniorrhaphy trial, 579 patients were randomized, while the bunionectomy study included 410 patients. The primary endpoint measured pain intensity http://www.streetinsider.com/Corporate+News/FDA+accepts+Viatris+drug+application+for+fast-acting+meloxicam+pain+treatment/26510552.html Mon, 18 May 2026 08:02:42 -0400 VTRS FDA accepts Viatris drug application for fast-acting meloxicam pain treatment http://www.streetinsider.com/FDA/FDA+accepts+Viatris+drug+application+for+fast-acting+meloxicam+pain+treatment/26510552.html <p>The U.S. Food and Drug Administration has accepted Viatris Inc.'s (NASDAQ: VTRS) new drug application for MR-107A-02, a fast-acting meloxicam formulation intended to treat moderate-to-severe acute pain. The FDA assigned a PDUFA goal date of December 27, 2026.</p><p>The application is supported by data from two Phase 3 clinical trials that evaluated the drug following herniorrhaphy and bunionectomy surgeries. Both randomized, double-blind studies compared the investigational drug against placebo and included tramadol as an active control to validate the pain models.</p><p>In the herniorrhaphy trial, 579 patients were randomized, while the bunionectomy study included 410 patients. The primary endpoint measured pain intensity http://www.streetinsider.com/FDA/FDA+accepts+Viatris+drug+application+for+fast-acting+meloxicam+pain+treatment/26510552.html Mon, 18 May 2026 08:02:42 -0400 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html <div class="xn-content"> <p class="prntac"><i>FDA PDUFA Goal Date Set for <chron>Dec. 27, 2026</chron></i></p><p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690420-1&h=3537581239&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc.</span></a> (Nasdaq: VTRS), a global healthcare company, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of <chron>Dec. 27, 2026</chron>. Acute pain affects more than 80 million individuals in <location value="LC/us" idsrc="xmltag.org" >the United States</location> each year, http://www.streetinsider.com/PRNewswire/U.S.+FDA+Accepts+Viatris+New+Drug+Application+for+Fast-Acting+Meloxicam+for+the+Treatment+of+Moderate-to-Severe+Acute+Pain/26510498.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.48105830 VTRS Form 8-K Viatris Inc For: May 15 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viatris+Inc+++++++++++++++For%3A+May+15/26506534.html si-local-file:///var/storage/secattach/20260515/26506534.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viatris+Inc+++++++++++++++For%3A+May+15/26506534.html Fri, 15 May 2026 16:34:00 -0400 O.48105830 VTRS Form 8-K Viatris Inc For: May 15 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viatris+Inc+++++++++++++++For%3A+May+15/26506534.html si-local-file:///var/storage/secattach/20260515/26506534.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viatris+Inc+++++++++++++++For%3A+May+15/26506534.html Fri, 15 May 2026 16:34:00 -0400 O.48105830 VTRS Viatris (VTRS) PT Raised to $20 at Truist Securities http://www.streetinsider.com/Analyst+PT+Change/Viatris++%28VTRS%29+PT+Raised+to+%2420+at+Truist+Securities/26455059.html Truist Securities analyst Les Sulewski raised the price target on Viatris (NASDAQ: VTRS) to $20.00 (from $18.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Viatris++%28VTRS%29+PT+Raised+to+%2420+at+Truist+Securities/26455059.html Thu, 07 May 2026 17:04:58 -0400 VTRS Viatris to Present at the Bank of America Securities 2026 Healthcare Conference http://www.streetinsider.com/Press+Releases/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=4211627692&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc</span></a>. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the <span>Bank of America Securities</span> 2026 Healthcare Conference on <chron>Tuesday, May 12, 2026</chron>, at <chron>8 a.m. PT</chron> / <chron>11 a.m. ET</chron>.</p><p>Investors and the general public are invited to listen to the live webcast of the event at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=2153986746&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4565015-1%26h%3D494588074%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4433168-1%2526h%253D3236195357%2526u%253Dhttps%25253A%25252F%25252Finvestor.viatris.com%25252Fevents-and-presentations%2526a%253Dinvestor.viatris.com%26a%3Dinvestor.viatris.com&a=investor.viatris.com." target="_blank" rel="nofollow">investor.viatris.com.</a> An archived version of the presentation will be available following the live event and can be accessed at the same location for a http://www.streetinsider.com/Press+Releases/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html Thu, 07 May 2026 16:30:00 -0400 O.48105830 VTRS Viatris to Present at the Bank of America Securities 2026 Healthcare Conference http://www.streetinsider.com/Press+Releases/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=4211627692&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc</span></a>. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the <span>Bank of America Securities</span> 2026 Healthcare Conference on <chron>Tuesday, May 12, 2026</chron>, at <chron>8 a.m. PT</chron> / <chron>11 a.m. ET</chron>.</p><p>Investors and the general public are invited to listen to the live webcast of the event at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=2153986746&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4565015-1%26h%3D494588074%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4433168-1%2526h%253D3236195357%2526u%253Dhttps%25253A%25252F%25252Finvestor.viatris.com%25252Fevents-and-presentations%2526a%253Dinvestor.viatris.com%26a%3Dinvestor.viatris.com&a=investor.viatris.com." target="_blank" rel="nofollow">investor.viatris.com.</a> An archived version of the presentation will be available following the live event and can be accessed at the same location for a http://www.streetinsider.com/Press+Releases/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html Thu, 07 May 2026 16:30:00 -0400 O.48105830 VTRS Viatris to Present at the Bank of America Securities 2026 Healthcare Conference http://www.streetinsider.com/PRNewswire/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=4211627692&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc</span></a>. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the <span>Bank of America Securities</span> 2026 Healthcare Conference on <chron>Tuesday, May 12, 2026</chron>, at <chron>8 a.m. PT</chron> / <chron>11 a.m. ET</chron>.</p><p>Investors and the general public are invited to listen to the live webcast of the event at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=2153986746&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4565015-1%26h%3D494588074%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4433168-1%2526h%253D3236195357%2526u%253Dhttps%25253A%25252F%25252Finvestor.viatris.com%25252Fevents-and-presentations%2526a%253Dinvestor.viatris.com%26a%3Dinvestor.viatris.com&a=investor.viatris.com." target="_blank" rel="nofollow">investor.viatris.com.</a> An archived version of the presentation will be available following the live event and can be accessed at the same location for a http://www.streetinsider.com/PRNewswire/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html Thu, 07 May 2026 16:30:00 -0400 O.48105830 VTRS Viatris to Present at the Bank of America Securities 2026 Healthcare Conference http://www.streetinsider.com/PRNewswire/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.pittbr" idsrc="xmltag.org" >PITTSBURGH</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=4211627692&u=https%3A%2F%2Fwww.viatris.com%2Fen&a=Viatris+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:VTRS" idsrc="xmltag.org" >Viatris Inc</span></a>. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the <span>Bank of America Securities</span> 2026 Healthcare Conference on <chron>Tuesday, May 12, 2026</chron>, at <chron>8 a.m. PT</chron> / <chron>11 a.m. ET</chron>.</p><p>Investors and the general public are invited to listen to the live webcast of the event at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682901-1&h=2153986746&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4565015-1%26h%3D494588074%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4433168-1%2526h%253D3236195357%2526u%253Dhttps%25253A%25252F%25252Finvestor.viatris.com%25252Fevents-and-presentations%2526a%253Dinvestor.viatris.com%26a%3Dinvestor.viatris.com&a=investor.viatris.com." target="_blank" rel="nofollow">investor.viatris.com.</a> An archived version of the presentation will be available following the live event and can be accessed at the same location for a http://www.streetinsider.com/PRNewswire/Viatris+to+Present+at+the+Bank+of+America+Securities+2026+Healthcare+Conference/26454108.html Thu, 07 May 2026 16:30:00 -0400 O.48105830 VTRS Form 10-Q Viatris Inc For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Viatris+Inc+++++++++++++++For%3A+Mar+31/26452755.html si-local-file:///var/storage/secattach/20260507/26452755.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Viatris+Inc+++++++++++++++For%3A+Mar+31/26452755.html Thu, 07 May 2026 16:04:00 -0400 O.48105830 VTRS Form 10-Q Viatris Inc For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Viatris+Inc+++++++++++++++For%3A+Mar+31/26452755.html si-local-file:///var/storage/secattach/20260507/26452755.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Viatris+Inc+++++++++++++++For%3A+Mar+31/26452755.html Thu, 07 May 2026 16:04:00 -0400 O.48105830 VTRS